title: Danazol therapy for thrombocytopenia in patients with myelodysplastic syndromes.
authors.affiliation: First Department of Internal Medicine, University of Athens School of Medicine, Laikon General Hospital, Athens, Greece. jbnv@otenet.gr
authors.forename: Nora
authors.initials: N
authors.lastname: Viniou
authors.forename: Eleni
authors.initials: E
authors.lastname: Plata
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
authors.forename: Eleni
authors.initials: E
authors.lastname: Variami
authors.forename: John
authors.initials: J
authors.lastname: Meletis
authors.forename: George
authors.initials: G
authors.lastname: Vaiopoulos
authors.forename: Dimitris
authors.initials: D
authors.lastname: Loukopoulos
authors.forename: Georgia
authors.initials: G
authors.lastname: Chatzidimitriou
authors.forename: Xenophon
authors.initials: X
authors.lastname: Yataganas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003613:Danazol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications*; D010976:Platelet Count; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D003613:Danazol